Middle Cerebral Artery Aneurysm Trial (MCAAT)
-
- STATUS
- Recruiting
-
- End date
- Jan 1, 2028
-
- participants needed
- 400
-
- sponsor
- University of Alberta
Summary
Intracranial aneurysms located on the middle cerebral artery (MCA) are considered by many surgeons to represent a distinct subgroup of aneurysms for which clipping may still be the best management option. Most MCA aneurysms are accessible, proximal control can readily be secured in case of rupture, and clip application can typically proceed without requiring the dissection of perforating arteries. In comparison, certain anatomic features of MCA aneurysms such as a wide neck, often including a branch artery origin, frequently render endovascular management more difficult. New endovascular devices were and continue to be introduced to address these anatomic difficulties, including stents, flow diverters, and intra-saccular flow disruptors (ISFDs) such as the WEB. Thus, while most aneurysms are increasingly treated with endovascular methods, many MCA aneurysm patients are still managed surgically, but convincing evidence of which management paradigm is best is lacking.
Description
The subgroup results of ruptured MCA aneurysms taken from ISAT-2 has recently been published. This also suggested that better efficacy could be obtained with surgical management of ruptured MCA aneurysms, with a similar number of residual aneurysms at 1 year in each group (4 surgery, 5 endovascular), but 2 rebleedings from coiled aneurysms (one fatal) and 4 other aneurysms retreated due to growing recurrences discovered on short-term follow-up. Although the ISAT has shown that good-grade, small, anterior circulation aneurysms patients have better 1 year clinical outcomes after being coiled, which was further supported by the Barrow Ruptured Aneurysm Trial (BRAT) study, there are several reasons to suspect that those results do not apply to aneurysms located at the MCA bifurcation. Only 14% of aneurysms in ISAT were on the MCA, likely because lesions in this location were preferentially treated with surgery. Even after selection, the MCA subgroup results were similar for coiling and clipping (RR: 1.01 (0.71-1.45)).
First, the number of selected MCA aneurysm patients included in ISAT was disproportionately small (301/2143 or 14%, as compared to 38% in ISAT-2) and they were recruited between 1994 and 2004, a time when only simple coiling was available. The overall trial result of superior clinical outcomes at 1 year was not confirmed for MCA aneurysms. The clinical primary endpoint of mRS >2 was reached in 39/139 clipped (28.1%, 95% CI:0.21-0.36), and 46/162 coiled patients (28.4%, 95% CI:0.22-0.36).
The suspicion that only selected MCA aneurysm patients were judged eligible for endovascular treatment at the time of ISAT is supported by the pre-randomized BRAT study: Of 61 patients with ruptured MCA aneurysms included between 2003 and 2007, 30 were assigned clipping and 31 coiling. Twenty-one of the 31 (68%) endovascular patients were crossed-over to the surgical arm.15 The Finnish RCT on clipping versus coiling reported only 19 ruptured MCA aneurysms because 59 MCA aneurysm patients were excluded.
If most MCA aneurysms can now be treated endovascularly, clinical results of contemporary technical achievements remain to be properly compared to surgical clipping. In particular, although overall clinical results were similar at one year in ISAT-2, rebleedings and retreatments after endovascular treatment remain worrisome.
The final argument for a new trial dedicated to MCA aneurysms has to do with the eventual interpretation of trial results. ISAT-2 was designed to be, and can still be considered a continuation of the original ISAT trial, with a superiority hypothesis in favor of endovascular treatment. The results presented here suggest that this hypothesis may not be appropriate for ruptured MCA aneurysms. Showing a result for a MCA subgroup that differs from the overall results at the end of ISAT-2 risks being scientifically problematic just as in the original ISAT.
Taken together, the available data and foregoing rationale are sufficient to warrant the conduct of a separate trial of surgical clipping versus endovascular treatment for MCA aneurysms, both ruptured and unruptured. MCAAT will provide a transparent care trial context for clinicians to manage patients with MCA aneurysms.
Details
| Condition | Middle Cerebral Artery Aneurysm |
|---|---|
| Treatment | surgical management, Endovascular management |
| Clinical Study Identifier | NCT05161377 |
| Sponsor | University of Alberta |
| Last Modified on | 4 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer